TP53 and central nervous system cancer: Gliomas with NTRK fusions have been previously reported to possess co-occurring genetic alterations such as IDH [18, 21, 39, 56], H3.3 K27M [52], H3F3A [9], EGFR amplification [21, 28, 56], EGFRvIII [21], PTEN [9, 21, 28], CDKN2A/2B deletion [9, 22, 28, 39, 52, 55, 57], CDKN2C deletion [28], TP53 mutations/inactivation [21, 39, 52, 57], and ATRX [39], among others [21].